

00/17/00

**UTILITY
PATENT APPLICATION
TRANSMITTAL**
(Only for new nonprovisional applications under
37 C.F.R. 1.53(b))

Attorney Docket No. 2896.1002001
First Named Inventor or Application Identifier Klaus Unsicker
Express Mail Label No. EJ611948809US

C675 U.S. PTO
09/521275

03/17/00

Title of Invention

CYTOKINES HAVING NEUROTROPHIC ACTIVITY

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

1. Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. Specification **Total Pages 26**
(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to microfiche Appendix
- Background of the Invention
- Summary of the Invention
- Brief Description of the Drawings
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. Drawing(s) (35 U.S.C. 113) **Total Sheets 20**
[] Formal [] Informal

4. Oath or Declaration/POA **[Total Pages []]**

- a. Newly executed (original or copy)
- b. Copy from a prior application (37 C.F.R. 1.63(d))
(for continuation/divisional with Box 17 completed)
[NOTE Box 5 below]
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. Computer Readable Copy
- b. Paper Copy (identical to computer copy)
- [] Pages

c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. Assignment Papers (cover sheet & documents)

9. 37 C.F.R. 3.73(b) Statement [] Power of Attorney
(when there is an assignee)

10. English Translation Document (if applicable)

11. Information Disclosure Statement (IDS)/PTO-1449 [] Copies of IDS Citations

12. Preliminary Amendment

13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. Small Entity [] Statement filed in prior application, status still proper and desired

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Other: Preliminary Remarks


17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

[] Continuation [] Divisional [] Continuation-in-part (CIP) of prior application No.: PCT/EP/98/06004
(U.S. Designated)

Prior application information: Examiner: Group Art Unit:

18. CORRESPONDENCE ADDRESS

NAME	Doreen M. Hogle, Esq., HAMILTON, BROOK, SMITH & REYNOLDS, P.C.			
ADDRESS	Two Militia Drive			
CITY	Lexington	STATE	MA	ZIP CODE
COUNTRY	USA	TELEPHONE	(781) 861-6240	FAX (781) 861-9540

Signature		Date	March 17, 2000
Submitted by Typed or Printed Name	Anabela Cristina Taylor		Reg. Number 38,999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Klaus Unsicker, Jens Pohl, Michael Paulista and Rolf Bechtold
Application No.: Continuation Application of PCT/EP98/06004 (U.S. Designated)
Filed: March 17, 2000
For: Cytokines Having Neurotrophic Activity

Date: 3-17-00

EXPRESS MAIL LABEL NO. EJ611948809US

PRELIMINARY REMARKS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

These remarks are filed together with the Continuation Patent Application of PCT/EP98/06004, filed on September 21, 1998, which designated the US and claims priority to European Patent Application No. 97 116 373.8 filed on September 19, 1997.

With respect to PCT/EP98/06004, the present specification includes, at page 1, a related applications paragraph which indicates that the present application is a continuation. Section headings have been added or changed. The abstract has been moved to the end of the specification and is presented on a separate sheet.

Figures 2 and 5 have been relabeled as 2A-2F and 5A-5B, respectively. Figure legends, under the Brief Description of the Drawings section heading, have been modified to specifically identify the number and letter of corresponding Figures.

No new matter has been introduced.

If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (781) 861-6240.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anabela C. Taylor
Anabela Cristina Taylor
Registration No. 38,999
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799
Dated: March 17, 2000

-1-

Date: 3-17-00 Express Mail Label No. E5611948809 US

Inventor(s): Klaus Unsicker, Jens Pohl, Michael Paulista and
Rolf Bechtold

Attorney's Docket No.: 2896.1002001

CYTOKINES HAVING NEUROTROPHIC ACTIVITY

RELATED APPLICATION(S)

This application is a Continuation of PCT/EP98/06004 filed on September 21, 1998, which designated the U.S., which claims priority to European Patent Application 5 Number 97 116 373.8 filed on September 19, 1997, the entire contents of which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

The present invention relates to a pharmaceutical composition having neurotrophic activity, for treating peripheral and/or CNS-disorders in mammals.

10 GDF-5 is a bone morphogenetic protein like molecule which, similar to other members of the transforming growth factor beta (TGF- β) superfamily, has been implicated in neurotrophic functions. For example, TGF- β 1, - β 2, and - β 3, as well as activin A, bone morphogenetic proteins (BMP) -2, -4, -6, -7, -12, glial cell line-derived neurotrophic-like factors (GDNF-like), and GDF-5 have all been shown to promote *in vitro* the survival of midbrain dopaminergic neurons by various mechanisms. GDNF 15 also acts on a wide spectrum of peripheral neurons.

The discovery of GDNF as a neurotrophic factor for midbrain dopaminergic neurons was a hallmark in the search for novel molecules that may have relevance in the treatment of neurodegenerative diseases, as e.g. Parkinson's disease. The significance of

GDNF is further underscored by its efficacy in several animal models of PD including non-human primates, ubiquitous expression in neurons of the CNS, and its widening spectrum of responsive neuron populations. GDNF signals via the tyrosine kinase receptor c-ret in co-operativity with a GPI-linked α receptor, the GDNFR α . GDNF is a

5 member of the TGF- β superfamily, its closest relatives being neurturin. Targeted mutations of the GDNF or c-Ret genes have indicated that GDNF is essentially required for the development of the kidney, major portions of the enteric nervous system and the sympathetic superior cervical ganglion. However, GDNF does not support the survival of most peripheral neurons in low-density dissociated cultures and defined media.

10 Follow-up experiments in which GDNF has been shown to promote the survival of enriched peripheral autonomic and sensory neurons were all performed using serum throughout the whole culture period. Furthermore, the dopaminotrophic effect of GDNF was established in an extremely complex culture system where its most prominent effect did not become apparent until day 7 in culture.

15 TGF- β s are widely distributed and contextually acting cytokines with prominent roles in development and cell cycle control. TGF- β s have been implicated in the regulation of neuronal survival of e.g. motoneurons, sensory and midbrain dopaminergic neurons. It should be noted, however, that TGF- β shows no or marginal effects on highly enriched, serum-free neuron cultures, as e.g. sensory neurons.

20 Thus, the technical problem underlying the present invention is to provide a new system having improved neurotrophic activity, for the treatment of peripheral and/or CNS-disorders in mammals.

The solution to the above technical problem is achieved by the embodiments characterized in the claims.

25 In particular, the present invention relates to a pharmaceutical composition having a neurotrophic activity, comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof and optionally a pharmaceutically acceptable carrier and/or diluent, wherein at least one of said

cytokines is BMP, GDF, TGF- β or GDNF. The term "BMP" includes BMP-2, BMP-4, BMP-6, BMP-7, BMP-11 and BMP-12. The term "TGF- β " includes TGF- β 1, TGF- β 2 and TGF- β 3. The term "GDNF" includes GDNF, neurturin and persephin. The terms "functionally active derivative" and "functionally active part" refer to a proteinous compound exhibiting at least part of the biological function of the respective cytokine.

5 The cytokines used in the pharmaceutical composition according to the present invention may be selected from the group consisting of GDF such as GDF-5, GDF-6, GDF-7, GDF-8 and GDF-9, GDNF, TGF such as TGF- α or TGF- β , e.g. TGF- β 1, TGF- β 2 or TGF- β 3, activin A, BMP such as BMP-2, BMP-4, BMP-6, BMP-7, BMP-11, 10 BMP-12, BDNF, NGF, neurotrophines such as NT-3 or NT-4, EGF, CNTF and FGF such as FGF-2.

Preferred embodiments of the present invention the pharmaceutical composition comprise the following combinations: GDF-5 and NGF or NT-3 or GDNF, TGF- β and GDNF or FGF-2 or CNTF or NT-3 or NGF, NGF and BMP-4 or BMP-12, NT-3 and 15 BMP-2 or BMP-7 or BMP-12.

As a surprising fact, if at least one of BMP, GDF, TGF- β and GDNF is present in the above defined pharmaceutical composition, a synergistic effect can be observed resulting in an increased neurotrophic activity, as compared to e. g. known compositions without GDF and/or GDNF.

20 The pharmaceutical composition according to the present invention may be used for the treatment of peripheral and/or CNS-disorders in mammals, preferably in man, such as Parkinson's disease, Alzheimer's disease, ALS or other dementia, other neurodegenerative disorders of the central nervous system and peripheral neuropathies including diabetes, cisplatinium or other genetic or acquired peripheral nerve diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a comparison of dose-response curves of GDF-5 and NGF in cultures of E8 chick DRG. Data are shown as means \pm SEM from three independent experiments with triplicate cultures. *P < 0.05; **P < 0.01 significantly different from 5 untreated negative control values.

Figures 2A through 2F depict a same experiment as in Figure 1 except that (2A) BMP-2, (2B) BMP-4, (2C) BMP-6, (2D) BMP-7, (2E) BMP-11 and (2F) BMP-12 have been used in the respective composition.

Figure 3 depicts the co-treatment of E8 DRG neurons for 48 hours with GDF-5 10 at a serial dilution range and NT-3 at a constant concentration of 2.5 ng/ml (---). For comparison serial dilutions of GDF-5 (-▲-) as well as NT-3 (....■...) are given. Surviving neurons were counted in triplicate determinations of at least two independent experiments. Values given are means \pm SEM. Significance was derived from the 15 comparison between neuronal numbers after GDF-5 plus NT-3 (2.5 ng/ml) and the individual factors. *P < 0.05; **P < 0.01.

Figure 4 depicts the survival of E8 DRG neurons cultured for 48 hours in the presence of various trophic factors at saturating concentrations with or without the addition of GDF-5 at a constant concentration of 20 ng/ml. Values represent the means + SEM of at least two independent experiments with triplicate determinations. *P < 0.05 20 significant difference from neuronal numbers treated with NGF alone.

Figures 5A-5B depict the survival of E8 chick DRG neurons cultured for 48 hours in the presence of saturating concentrations of (5A) NGF (10 ng/ml) or (5B) NT-3 (10 ng/ml) applied separately or in combination with the indicated BMPs. Cultures were treated for 48 h. Values given are mean \pm SEM of quadruplicate determinations of at 25 least two independent experiments. *P < 0.05 significant difference from neuronal numbers treated with NGF or NT-3 alone.

Figures 6A-6D depict the survival of peripheral autonomic and sensor neurons by the synergistic action of GDNF and TGF- β . 6A, chick ciliary ganglionic (CG) neurons; 6B, dose-response curve for the combined action of GDNF and TGF- β ; 6C, chick dorsal root ganglionic (DRG) neurons; 6D, chick sympathetic ganglionic (SG) neurons. Neurons from the respective ganglia were isolated at embryonic day 8 (E8) and grown under the indicated conditions. Neurons were maintained in serum containing medium (grey bars; 6A, 6C, 6D) or in serum free medium (white bars: 6A, 6B, 6C, 6D). In the presence of 10% horse serum addition of a saturating concentration of GDNF promoted survival of each of the three neuron populations at levels identical to those achieved by addition of the respective neurotrophic factor (CNTF for CG, NGF for DRG and SG neurons) to serum-free culture media. Addition of a neutralizing antibody to TGF- β 1, - β 2, and - β 3 reduced neuron survival to levels seen with the addition of serum alone indicating that GDNF required TGF- β in the serum to achieve its survival promoting effect. In serum-free conditions, GDNF and TGF- β 1, when added by themselves had virtually no survival promoting effect. However, when combined at optimal concentrations, both factors permitted neuron survival at levels identical to those achieved with the established neurotrophic factors CNTF and NGF, respectively.

Figures 7A-7F depict an assay as performed in figure 1 using neurons from the respective ganglia of chick E10 (7A, 7B, 7C) and E12 (7D, 7E, 7F) embryos. Data indicate that the GDNF/TGF- β synergism also applies to neurons at more advanced stages of development.

Figure 8 depicts the survival promoting effect of GDNF on rat embryonic mesencephalic dopaminergic neurons (E14) is dependent on the presence of TGF- β . Dissociated cultures were treated with GDNF (10 ng/ml), with GDNF in the presence of 25 anti-TGF- β 1, - β 2, - β 3 (10 μ g/ml), with TGF- β 3 (2 ng/ml) or without any growth factor added (control) for 8 days in culture. Numbers of dopaminergic neurons were determined by counting the numbers of tyrosine hydroxylase (TH) immunoreactive neurons.

Figure 9 depicts GDNF requires TGF- β *in vivo* for establishing its neurotrophic effect. Retrogradely labeled preganglionic (IML) neurons to the adrenal medulla (a) express cRet (b) and GFR α -1 (c) mRNAs. Cell death of the preganglionic neurons caused by adrenomedullectomy is fully prevented by substitution of GDNF into the 5 adrenal cavity (d). Co-application of a neutralizing TGF- β antibody significantly reduces neuroprotection by GDNF (e). LF, lateral funiculus of the spinal cord. Bar = 100 μ m.

Figures 10A-10B depict the mechanisms underlying the synergistic actions of GDNF and TGF- β . (10A) Wortmannin, a specific inhibitor of IP3 kinase abolishes 10 GDNF/TGF- β -mediated survival of chick ciliary ganglionic neurons indicating that IP3 kinase is an essential mediator in signal transduction of the combined action of GDNF and TGF- β . (10B) PIPLC, which liberates GPI-anchored cytokine receptors from the plasma membrane interferes, as expected, with the survival promoting effect of CNTF on chick ciliary ganglionic neurons, since CNTF employs a GPI-anchored alpha 15 receptor for signal transduction. PIPLC does not interfere with the survival promoting effect of FGF-2, which does not employ an alpha receptor for signaling. Treatment of isolated ciliary neurons with PIPLC significantly reduces the survival promoting effect of GDNF and TGF- β consistent with the essential role of a GPI-linked GDNF alpha receptor in GDNF signal transduction. Addition both, PIPLC and TGF- β to isolated 20 ciliary neurons, protects the GDNF alpha receptor indicating that the synergistic neurotrophic action of GDNF and TGF- β may be due to a protective action of TGF- β on the GDNF alpha receptor.

Figure 11 depicts the the soluble proteins of chromaffin granules promote the survival of chick ciliary ganglionic neurons at a level identical to that achieved with a 25 saturating concentration of CNTF (10 ng/ml). Addition of neutralizing antibodies to either GDNF (20 μ g/ml) or the TGF- β s TGF- β 1, - β 2 and - β 3 (10 μ g/ml) significantly reduces the promoting effect of VP. Addition of both antibodies completely abolishes

the neurotrophic effect of VP (0,5 ng/ml) indicating that GDNF and TGF- β are the long-sought ciliary neurotrophic proteins contained in VP.

Figure 12 depicts the effect of neutralizing endogenous TGF- β in mesencephalic neuron cultures. Numbers of surviving TH-immunoreactive neurons of mesencephalic cultures (E14/DIV8) after 8 days in culture treated with FGF-2 (10 ng/ml), medium only (control), in presence or absence of neutralizing antibodies to TGF- β 1/- β 2/- β 3 (10 μ g/ml). Data are given as mean \pm SEM (n=3), P-values are ***P < 0.001 for increased survival as compared with control cultures and +P < 0.05 or +++P < 0.001 for decreased survival following antibody treatment.

Figures 13A-13B depict the neutralizing endogenous TGF- β reduces the survival promoting effects of CNTF and FGF-2 on chick CG neurons. Cultures were treated with CNTF (13A) or FGF-2 (13B) alone (-●-) at the indicated concentrations or in combination with neutralizing antibodies (-■-) to TGF- β 1, - β 2, - β 3 (1 μ g/ml). Data are given as mean \pm SEM (n=3). P-values are *P < 0.05; **P < 0.01 for decreased survival in the combination of growth factor plus anti-TGF- β as compared to growth factor-treatment alone.

Figures 14A-14B depict TGF- β induces responsiveness of chick CG neurons to CNTF, NGF and NT-3. Cultures were treated with (14A) CNTF (5 or 0.3 ng/ml), Oncostatin M, LIF, IL-6 (at 10 ng/ml), or (14B) NGF, NT-3, NT-4 in the absence or presence of TGF- β (2.5 ng/ml). Data are given as percent of CNTF-plateau-survival as means \pm SEM (n=3). *P < 0.05, **P < 0.01 for increased survival in the combination with TGF- β 3 as compared to the corresponding single factor treatment alone.

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not

necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.

DETAILED DESCRIPTION OF THE INVENTION

A description of preferred embodiments of the invention follows.

5 The following examples illustrate the invention:

1. Synergistic effect between GDF-5 and BMP, respectively, with NT-3 or NGF

Dissociated cultures of embryonic chicken dorsal root ganglia (DRG) were generated as described in details by Kriegstein and Unsicker (Neurochem. Res., 21(7) 10 (1996) 843-850). Briefly, DRGs from white Leghorn chick embryos (day 8) were dissected in Ca^{2+} - Mg^{2+} free Hanks' balanced salt solution. After incubation in 0.08% trypsin for 15 min ganglia were dissociated by trituration. Cells were seeded in polyornithin-laminin coated 96-well microtiter plates (A/2 Costar) at a density of 1,200 cells/well. Growth factors were applied at the time of plating in a final volume of 50 ml 15 Dulbecco's Modified Eagle's Medium supplemented with 0.25% bovine serum albumin, N1 additives and 100 U/ml penicillin. As a positive control, nerve growth factor (NGF) was used at the saturating concentration of 5 ng/ml. After 48 h of incubation at 37°C in a humidified atmosphere containing 5% CO_2 , cultures were fixed with 2.5% glutaraldehyde. Neuronal cells were identified by their phase-bright and 20 neurite-bearing morphologies and counted within 30% of the total surface area using phase contrast microscopy. In the first set of experiments we tested the survival promoting effect of several growth factors of the bone morphogenetic protein family. Dose-response analysis of GDF-5 and BMP, respectively, utilizing a wide range of 25 serial dilutions, revealed that GDF-5 and all BMPs examined increased the number of surviving sensory neurons in a dose-dependent, saturable manner but at different

magnitude (Figs. 1 and 2). For example, GDF-5 can induce an approximately two-fold increase (at a saturating concentration of 20 ng/ml) in neuronal cell numbers, corresponding to about 20% of the NGF effect (Fig. 1). BMP-4 and BMP-7 showed approximately 35% of the maximal NGF effect (Fig. 2B and D, respectively), and

5 BMP-2, -6, -11 and -12 had also a significant effect (Fig. 2A, C, E and F, respectively).

Neurotrophic factors have been postulated to act in a finely tuned concert and sequence in determining neuronal survival. As shown in Fig. 3, addition of 2.5 ng/ml NT-3 to various concentrations of GDF-5 significantly increased DRG neuron survival above the NT-3 level indicating that NT-3 and GDF-5 can act synergistically. When

10 added at saturating concentrations the two factors failed to increase neuronal numbers significantly above the levels of each single factor. This indicates that GDF-5 and NT-3 affect identical or largely overlapping neuron populations. In contrast, addition of GDF-5 (20 ng/ml) to NGF (5 ng/ml) significantly increased neuronal cell numbers above values obtained for each single factor (Fig. 3). This indicates that GDF-5 and

15 NGF can promote different neuronal populations in our DRG culture system.

All other growth factors examined [brain-derived neurotrophic factor, BDNF; neurotrophin-4, NT-4; TGF- β 1 and - β 3, GDNF, epidermal growth factor, EGF; transforming growth factor- α , TGF- α ; fibroblast growth factor-2, FGF-2] show also synergistic or additive effects when added together with GDF-5 at any tested

20 concentrations (Fig. 4).

As shown in Figure 5A, NGF in combination with GDF-5, BMP-4, or BMP-12 significantly increased survival of DRG neurons beyond levels maintained by the single factors. GDF-5 and BMP-12 promoted the survival of a very small neuron population when added alone. However, when combined with NGF, the increase in cell numbers

25 was significantly higher than could be explained by simple addition. Therefore, these data indicate that GDF-5 and BMP-12 potentiate the NGF effect. The combination of BMP-4 with NGF show also significant effects. Figure 5B documents that the

promoting effects of GDF-5 and BMPs are also significant for NT-3. GDF-5, BMP-2, -7 and -12 significantly augmented the promoting effect of NT-3. In the case of GDF-5 and these BMPs together with NT-3 the results show that they promote the survival of largely none-overlapping neuron populations. Combined treatments with BMPs and

5 BDNF, NT-4, or GDNF indicate that these factors promote survival of largely overlapping neuron populations.

The present data demonstrate a survival promoting effect of GDF-5 and BMPs on a population of peripheral sensory neurons adding to the evidence that multifunctionality of GDF-5 and BMPs comprises a capacity as neurotrophic factors.

10 Furthermore, GDF-5 and BMPs can synergistically affect survival of neurotrophin-supported DRG neurons. Additive effects of NGF and BMPs indicate that the BMP-supported DRG subpopulation comprises NT-3- or BDNF-dependent rather than NGF-dependent DRG neurons. DRG neurons with a requirement for NT-3 belong to the category of large sensory neurons mediating proprioceptive inputs from muscle to

15 the spinal cord. BDNF-dependent sensory neurons comprise a probably heterogeneous population. Both populations may be putative targets for GDF-5 and BMPs consistent with their localization in the early developing limb. In the context of emerging evidence that TGF- β s can synergistically act with several neurotrophins the present data indicate that such a property can also be assigned to GDF-5 and BMPs. The present data are also

20 consistent with the notion that GDF-5 and BMPs can significantly reduce doses of neurotrophins required for supporting sensory neurons. Neurotrophins are currently in clinical trial for several forms of peripheral neuropathies. Therefore, the pharmaceutical composition according to the present invention has a bearing on the application of neurotrophins, in particular in neuropathies responding to NT-3.

25 2. **Synergistic effect of TGF- β with other neurotrophic factors and neuro-**
phins

The neurotrophic action of GDNF on several populations of peripheral and CNS neurons essentially requires TGF- β *in vitro* and *in vivo*.

GDNF has been proposed as a potent neurotrophic factor for cultured midbrain dopaminergic neurons, motoneurons, as well as peripheral autonomic and sensory 5 neurons. All of the above culture systems share significant cellular complexity and/or the use of serum resulting in uncontrolled trophic conditions. A well-known constituent of almost every cell type as well as serum is TGF- β . For example, confluent cultures of B49 cells (from which GDNF was isolated), BHK, COS cells and 3T3 fibroblasts (which are frequently used for transfection experiments) secrete within 24 h 0.2 to 0.4 10 ng/ml TGF- β into their culture medium, as determined by its biological activity. Different batches of fetal calf and horse sera contain varying, but significant amounts of TGF- β (0.1 - 0.2 ng/ml in culture media with 10% serum).

Using chick ciliary ganglionic neurons as an example, Figure 6A demonstrates that GDNF supplemented with 10% horse serum maintains neurons over a 24 h period 15 as effectively as a saturating concentration of CNTF (5 ng/ml). However, administering culture medium that had been preincubated with neutralizing antibodies to TGF- β (10 μ g/ml, known to neutralize >95% of 1 ng/ml of TGF- β isoforms - β 1, - β 2, and - β 3) significantly reduced the effect of GDNF showing that GDNF requires TGF- β for displaying its trophic effect. Consistent with this notion, switching from serum- 20 containing to a fully-defined culture medium both GDNF and TGF- β (each at the saturating amount of 2 ng/ml) showed only marginal survival promoting effects. However, when combined the two factors promoted neurons as effectively as CNTF. In order to determine dose-response relationships required for the synergistic effect of GDNF and TGF- β each single factor at a concentration of 2 ng/ml was titrated in 25 combination with serial dilutions of the other one. As shown in Figure 6B 60 pg/ml of

either factor combined with 2 ng/ml of the other factor represented the EC₅₀. The combination of 0.25 ng/ml and 2 ng/ml already elicited saturating effects. All isoforms of TGF- β (TGF- β 1, - β 2, and - β 3) were consistently equipotent under the conditions used (not shown).

5 To investigate whether the synergistic effect of GDNF and TGF- β also applied to other populations of peripheral neurons, identical experiments were performed using chick sensory (DRG) and paravertebral sympathetic neurons isolated from embryonic day (E) 8 embryos. As shown in Figure 6C and 6D GDNF and TGF- β when co-administered to serum-free cultures maintained sensory and sympathetic neurons, 10 respectively, as supported by a saturating concentration of NGF (5 ng/ml). Again, 10% horse serum substituted for TGF- β .

15 To exclude that the above effects are restricted to a brief developmental time window, the same set of experiments was performed on ciliary, sensory DRG and sympathetic neurons from E10 and E12 chick embryos. Figure 7A-F shows that at all ages and on all neuron populations studied co-administration of GDNF and TGF- β mimicked the survival promoting effect of CNTF or NGF, respectively.

20 As shown in Figure 8 GDNF and TGF- β each promoted the survival of dopaminergic neurons at 160% and 200%, respectively, of untreated control cultures. Combinations of the factors did not further enhance survival consistent with the presence of endogenous TGF- β at an amount of approximately 0.2 ng/ml. Addition of 25 neutralizing antibodies to TGF- β (10 μ g/ml) abolished the trophic effect of GDNF. Accordingly TGF- β is required to permit GDNF exerting its neurotrophic potential on both peripheral and CNS neurons.

To prove that GDNF required TGF- β for establishing its neurotrophic activity *in* 25 *vivo*, preganglionic neurons in the spinal cord of adult rats were deprived from their adrenal chromaffin target cells using unilateral surgical destruction of the rat adrenal medulla. This type of target deprivation causes the death of all preganglionic neurons to

the adrenal medulla at four weeks, as previously shown by Blottner and Baumgarten (Exp. Neurol. 118 (1992) 35-46). As can be seen in Figure 9a-c, preganglionic neurons express the GDNF receptors cRet and GFR- α 1. Figure 9d shows that the substitution of the target of the preganglionic neurons by administrating 1 μ g GDNF in a piece of 5 gelfoam to the medullectomized adrenal gland fully protected the neurons after four weeks. As shown in Figure 9e, co-administration of TGF- β -neutralizing antibodies prevented the protective effect of GDNF. This shows that the presence of endogenous TGF- β is essential for permitting a neurotrophic effect of GDNF *in vivo*.

TGF- β synergizes with GDNF by stabilizing or recruiting the GDNFR- α

10 To begin to characterize details of the specific signal transduction pathway employed by GDNF to cooperate with TGF- β , further studies were carried out regarding the question whether activation of PI-3 kinase that has been shown as an early event in GDNF/c-ret-mediated signal transduction was involved. Figure 10A shows that the specific PI-3 kinase inhibitor wortmannin at a concentration of 0.25 μ M completely 15 abolished the survival promoting effect of GDNF in conjunction with TGF- β on cultured ciliary neurons. Wortmannin did not interfere with the survival promoting effect of CNTF indicating that activation of PI-3 kinase is an essential event in mediating the survival promoting effect of GDNF/TGF- β , but not that of CNTF. Furthermore, this result indicates that wortmannin did not unspecifically compromise 20 survival.

25 A further question was whether TGF- β might be involved in the stabilization and recruitment of the GPI-linked GDNFR- α . Phosphatidylinositol-specific phospholipase C (PIPLC) at a concentration of 0.1 U/ml was used to hydrolyse the GPI-achored receptors on dissociated ciliary neurons prior to plating. This procedure effectively reduced the survival promoting effect of CNTF (which utilizes a GPI-

anchored GPAR α), without affecting the survival promoting effect of FGF-2 (Figure 10B). Hydrolysis of GPI-linked receptors significantly reduced the survival promoting effect of GDNF in its combination with TGF- β . However, when the PIPLC pretreatment was conducted in the presence of TGF- β (2 ng/ml TGF- β 1) the survival promoting effect of GDNF was maintained (Figure 10B). These data indicate an essential involvement of a GPI-linked receptor component in the neurotrophic effect of GDNF and a possible role of TGF- β in the stabilization and/or recruitment of the alpha receptor component.

10 TGF- β also mediates the neurotrophic action of FGF-2, CNTF and neurotrophins

Fibroblast growth factor (FGF)-2 is known to act as a neurotrophic factor for dopaminergic neurons in the ventral midbrain. Earlier studies suggested that the neurotrophic effect exerted by FGF-2 is mainly indirect and mediated by mesencephalic ganglia (Engle and Bohn, J. Neurosci. 11 (1991) 3070-3078). As TGF- β is known to be a product of astroglial cells, it was tested whether TGF- β -neutralizing antibodies can abolish the neurotrophic effect of FGF-2 on cultured neurons derived from the embryonic midbrain floor. Figure 12 shows that the treatment of the cultured neurons with FGF-2 (10 ng/ml) led to an 1.7fold increase in survival of the cells compared to the negative control (medium alone). In contrast, addition of antibodies specific for TGF- β 1/- β 2/- β 3 completely abolished the survival promoting effect of FGF-2. These data show that the neurotrophic effect of FGF-2 on dopaminergic neurons in the ventral midbrain is mediated by TGF- β .

25 TGF- β was able to operate synergistically with FGF-2 and CNTF in the control of chick ciliary ganglion (CG) neuron survival. An antibody recognizing the TGF- β isoforms - β 1/- β 2/- β 3 was employed to immunoneutralize TGF- β in cultures of CG neurons treated with CNTF or FGF-2, respectively (Fig. 13). Neutralization of TGF- β

reduced CNTF- or FGF-2-mediated neuron survival by 40 to 60%. These data indicate that TGF- β released from cultured CG neurons synergistically acts with exogenous neurotrophic factors to assure neuron survival.

CNTF shares receptor and signal transduction components with members of a 5 family of neuropoetic cytokines, which include leukemia inhibiting factor (LIF), oncostatin M (OSM), and interleukin-6 (IL-6) (Stahl and Yancopoulos, *J. Neurobiol.* 25 (1994) 1454-1466). As shown in Figure 14A, TGF- β clearly augmented the efficacy of a non-saturating concentration of CNTF in terms of promoting CG neurons survival. OSM, LIF, and IL-6 did not support CG neurons, and further addition of TGF- β did not 10 increase the effects of these cytokines beyond background levels. Neurotrophins are not established trophic factors for CG neurons (Collins, *Brain Res.* 467 (1988) 111-116). However, in combination with TGF- β , both NGF and NT-3 promoted survival at 35 to 15 40% of the CNTF-plateau (Fig. 14B). Although expression of trkA receptors, which permit signalling of NGF and NT-3 on CG neurons has not been shown as yet, the data presented indicate that TGF- β may cooperate neurotrophin receptor-mediated signalling on CG neurons.

Experimental Procedures

Materials

CMF: $\text{Ca}^{2+}/\text{Mg}^{2+}$ -free Hanks' balanced salt solution, DMEM: Dulbecco's 20 modified Eagle's medium, and PSN were purchased from Gibco. Poly-L-ornithine, laminin, A23187, carbachol, and verapamil was purchased from Sigma, bovine serum albumin (BSA) was from Serva (Heidelberg, Germany) and PIPLC from Boehringer Mannheim (Germany).

Horse serum (HS) was purchased from Gibco, fetal calf serum (FCS) batches 1 and 2 were from PAA, FCS batches 3 and 4 were from Euro and FCS batches 5 and 6 were from PAN.

Growth factors

5 Growth factors were obtained from Boehringer Mannheim (NGF, 2.5 S NGF and recombinant human (rh) LIF), IC Chemikalien (recombinant rat (rr) CNTF, rh GDNF, rh Oncostatin M (OSM), rh IL-6, rh NT-3, rh NT-4 and rh BDNF) and Genetics Institute, Inc. (rh BMP-2, rh BMP-4, rh BMP-6, rh BMP-7, rh BMP-11 and rh BMP-12). For the experiments according to Fig. 5, GDF-5 was purchased from BIOPHARM, 10 otherwise it was produced as described (Kriegstein et al., J. Neurosci. Res., 42(5) (1995) 724-732). Rh FGF-2 for the experiments according to Fig. 12 was obtained from Progen, and for all other experiments from IC Chemikalien. Lyophilized factors were resuspended in culture medium (see below) to give a final concentration of 1 µg/ml and stored in aliquots of 50-100 µl at -70°C until use.

15 Antibodies

The neutralizing antibody to TGF β -1,2,3 was purchased from Genzyme and to GDNF from Santa Cruz Biotechnology.

Agarose conjugated antibodies to TGF β -1 and to GDNF were from Santa Cruz Biotechnology. The peroxidase conjugated α -rabbit antibody was purchased from 20 Sigma.

Animals for experiments according to Figs. 1, 3, 4, 6, 7, 8 and 11

Fertilized white Leghorns chick eggs were obtained from a local aviary and incubated in a humidified egg chamber at 37.8°C.

Animals for experiments according to Figs. 2, 5 and 12-14

Fertilized white Leghorns chick eggs were obtained from a local aviary and
5 incubated in a humidified egg chamber at 38°C until E8.

Cell culture for experiments according to Figs. 1, 3, 4, 6, 7, 8 and 11

Assays of neurotrophic activity:

Embryonic chick ciliary (CG), dorsal root (DRG), and sympathetic (SG) ganglia at embryonic day(s) (E) 8, 10, and 12, were dissected, freed from nerve roots and
10 connective tissue and collected in CMF. Ganglia were incubated in trypsin (ICN), washed and dissociated by trituration using fire-polished Pasteur pipettes. Cultures were set up in 96-well microtiter plates (Costar, A/2), precoated with poly-L-ornithine and laminin at a density of 1,200-1,500 cells/well in DMEM supplemented with N1 additives, 0.25% BSA, and 0.1% PSN (DME/N1) and incubated at 37°C in a
15 5% CO₂ incubator.

At appropriate times (CG: 24 h, DRG: 48 h, SG: 72 h) cultures were fixed by addition of 2.5% glutardialdehyde in phosphate buffered saline (PBS). Numbers of surviving neurons were determined by direct counting of 30% of the surface area using phase contrast microscopy.

20 Treatment with PIPLC:

Phosphatidylinositol-specific phospholipase C (PIPLC) is an enzyme that specifically cleaves glycosyl-phosphatidylinositol (GPI) linkages.

Embryonic chick ciliary ganglionic neurons (E8) were isolated and seeded as described before. Neurons were incubated for 1 h at 37°C with I) 100 mU PIPLC or II) 100 mU

5 PIPLC + 2 ng/ml TGF β or III) without enzyme and then growth factors were added.

The number of surviving neurons was determined 24 h later.

Preparation of chromaffin cells and release studies:

The isolation of bovine adrenal medullary chromaffin cells was performed by collagenase digestion and Percoll gradient centrifugation essentially as described by

10 Unsicker et al. (Neuroscience 5 (1980) 1445-1460). Chromaffin cells were seeded into 25 cm² plastic culture flasks (Falcon) at densities of 1 x 10⁶ cells/ml and routinely had a purity of at least 90-95%. The culture medium consisted of DME/N1 and for stimulation experiments, the culture medium was replaced after 30 h with prewarmed stimulation buffer containing I) carbachol (100 μ M) or II) carbachol (100 μ M) plus 15 verapamil (10 μ M) or III) the Calcium ionophore A23187 (2 μ M) or IV) no additives and incubated for 15 min at 37°C. After collection of the stimulation buffer an aliquot for determination of catecholamines by HPLC (Müller et al., J. Neurosci. Methods 4 (1981) pages 39-52) was removed, and the remainder was prepared for protein analysis.

Cell lines:

20 The cell lines B49, 3T3 and COS were grown in 10% FCS/DMEM with 1% PSN and the cell line BHK was set up in DMEM/F 12 with 5% FCS and 1% PSN in plastic culture flasks.

Conditioned medium of these different cell lines was collected and aliquots were stored at -80°C and then prepared for MLEC-bioassay to determine TGF β activity.

Proteins from bovine chromaffin granules

The isolation of bovine chromaffin granules was according to the protocol by Winkler et al. (Handbook of Physiology, Section 7, Vol. 6, pp. 321-339). Granules were lysed by a freeze-thaw cycle in a 10 mM phosphate buffer (pH 7.2) and the soluble

5 proteins were separated from membranes by ultracentrifugation at 100,000 g for 30 min. The supernatant then was dialyzed overnight against 10 mM phosphate buffer, pH 7.2 by using membrane tubing (Spectropor) with a 3.5 kDa cutoff. Aliquots were stored at -80°C.

Agarose conjugate/Western blots

10 To 1 ml of the stimulation buffer with or without additives from chromaffin cells 10 μ l of the antibody agarose conjugate were added and incubated at 4°C overnight with mixing. The pellet was washed with PBS and then resuspended in 50 μ l of electrophoresis sample buffer and boiled for 2 minutes. Samples were separated by electrophoresis on a 12.5% SDS-PAA gel and transferred to nitrocellulose membrane
15 (Hybond, Amersham). The nitrocellulose membrane was blocked with 3% low fat milk powder/0.1% BSA in Tris buffered saline (TBS, pH 7.3), incubated with primary antibody (1:200 in 0.1% BSA/TBS) overnight at 4°C followed by peroxidase conjugated secondary antibody (1:2000 in 0.1% BSA/TBS). Finally the membrane was developed using the Amersham enhanced chemiluminescence (ECL) detection system.

20 Assay for TGF- β 's

Determination of TGF- β activity was performed by using the mink lung epithelial cell (MLEC) (kindly provided by Dr. Rifkin, New York University, New York, USA) bioassay (Abe et al., Anal. Biochem. 216 (1994) 276-284). Transfected

MLEC cultures were set up in a 96-well microtiter plate (Costar) at a density of 1.6 x 10⁴ cells/well in DMEM (high glucose) with 10% FCS and geneticin (250µg/ml) and allowed to attach for 3 h at 37°C in a 5% CO₂ incubator. The medium was then replaced with 100 µl of test sample in DME/N1 (activated with HCl) and incubated overnight at 5 37°C in a 5% CO₂ incubator. Cells were washed twice with PBS and lysed by using 100 µl of lysis buffer (Promega) for 2-3 h at RT. To determine TGFβ activity, 80 µl of the lysates were transferred to a test tube and analyzed using a Luminometer (Lumat, Berthold/Germany) by 100 µl injections of luciferase reagent (Promega). Luciferase activity was reported as relative light units (RLU) and all assays were performed in 10 triplicate.

Statistics

Statistical comparisons were made with one-way ANOVA, included in the MicroCalOrigin software. Differences were considered statistically significant at * P < 0.05, ** P < 0.005, and *** P < 0.0005.

15 Cell culture for experiments according to Figs. 2, 5 and 12-14

Dissociated cultures of embryonic chicken dorsal root ganglia (DRGs) were generated as described in details by Kriegstein and Unsicker (Dev. Brain. Rees. 93 (1996) 10-17). Briefly, DRGs were dissected in Ca²⁺-Mg²⁺ free Hank's balanced salt solution (CMF). After incubation in 0.08% trypsin (BioWhittaker) for 15 min, ganglia 20 were dissociated by gentle trituration using fire-polished Pasteur pipettes. Cells in suspension (neuron/non-neuron ratio 1:2) were seeded in polyornithin-laminin coated 96-well microtiter plates (A/2 Costar) at a density of 1,200 cells/well. Growth factors were applied at the time of plating in a final volume of 50 µl Dulbecco's Modified Eagle's Medium supplemented with 0.25% bovine serum albumin, N1 additives

(Bottenstein et al., *Exp. Cell Res.* 125 (1980) 183-190) and 100 U/ml penicillin. As a positive control, nerve growth factor (NGF) was used at the saturating concentration of 10 ng/ml. After 48 h of incubation at 37°C in a humidified atmosphere containing 5% CO₂, cultures were fixed with 2.5% glutaraldehyde in phosphate buffered saline (PBS).

5 Neuronal cells were identified by their phase-bright and neurite-bearing morphologies and counted within 30% of the total surface area using phase contrast microscopy. All experiments were performed in at least triplicate in two independent experiments. Data are presented as mean \pm SEM. Statistical comparisons were made with student's double *t*-test, ANOVA and MicrocalOrigin software. Differences were considered statistically
10 significant at *P < 0.05, **P < 0.01, ***P < 0.001.

Assay for preganglionic neuron protection *in vivo*

Adrenomedullectomy was performed on adult male Hanover-Wistar rats. Preganglionic neurons in the spinal cord innervating adrenal medullary chomaffin cells were identified by retrograde tracing with Fast Blue or Fluoro-Gold (FG). Factors (1 μ g
15 each) were soaked in gelfoam (Spongostan, Ferrosan, Soeburg, Denmark) prior to implantation into unilaterally medullectomized adrenal glands. Numbers of FG-labeled preganglionic neurons were determined by cell counts of complete series of longitudinal sections through spinal cord segments T7-T10 four weeks post-surgery. Only brightly fluorescent neurons containing a clearly visible nucleus were counted. Total numbers
20 were corrected for possible double counts of split nuclei according to Abercombie's formula. Numbers of preganglionic neurons to the adrenal medulla surviving in sham-operated animals and on the unlesioned side were set as 100%. Data are given as mean values \pm SEM and the statistical significance of intergroup differences was determined by Student's *t*-test.

In situ hybridization

In situ hybridizations were performed on paraffin sections of the thoracic spinal cord essentially as described in Arumäe et al. (J. Cell Biol. 122 (1993) 1053-1065).

Probes were derived from rat GFR α -1, nucleotides 294-1039, and mouse cRet, 5 nucleotides 2534-3217. After hybridization, all sections were dipped and exposed for 2-3 weeks, counterstained with haematoxylin, air dried and embedded in DPX. No hybridization signal was detected with the probes on sense orientation.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that

10 various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

CLAIMS

What is claimed is:

1. A pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof wherein at least one of said cytokines is BMP, GDF, TGF- β or GDNF.
5
2. The pharmaceutical composition according to Claim 1, wherein the cytokines are selected from the group consisting of GDF, GDNF, TGF, activin A, BMP, BDNF, NGF, NT, EGF, EGF, CNTF and FGF.
- 10 3. The pharmaceutical composition according to Claim 1, comprising GDF-5 and NGF.
4. The pharmaceutical composition according to Claim 1, comprising GDF-5 and NT-3.
- 15 5. The pharmaceutical composition according to Claim 1, comprising GDNF and TGF- β .
6. The pharmaceutical composition according to Claim 1, comprising GDF-5 and GDNF.

7. The pharmaceutical composition according to Claim 1, comprising TGF- β and FGF-2.
8. The pharmaceutical composition according to Claim 1, comprising TGF- β and CNTF.
- 5 9. The pharmaceutical composition according to Claim 1, comprising TGF- β and NT-3.
10. The pharmaceutical composition according to Claim 1, comprising TGF- β and NGF.
- 10 11. The pharmaceutical composition according to Claim 1, comprising BMP-4 and NGF.
12. The pharmaceutical composition according to Claim 1, comprising BMP-12 and NGF.
13. The pharmaceutical composition according to Claim 1, comprising BMP-2 and NT-3.
- 15 14. The pharmaceutical composition according to Claim 1, comprising BMP-7 and NT-3.
15. The pharmaceutical composition according to Claim 1, comprising BMP-12 and NT-3.

16. The pharmaceutical composition of Claim 1 further comprising a pharmaceutically acceptable carrier, diluent or any combination thereof.

CYTOKINES HAVING NEUROTROPHIC ACTIVITY

ABSTRACT OF THE DISCLOSURE

The present invention relates to a pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines, wherein at least one of said cytokines is BMP, GDF, TGF- β or GDNF.




Fig. 1




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D




Fig. 2E




Fig. 2F




Fig. 3




Fig. 4




Fig. 5A




Fig. 5B

Fig. 6

A




Fig. 6

B




Fig. 6 C

DRG/ES-Assay




Fig. 6 D




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 7D




Fig. 7E





Fig. 7F

SG/E12-Assay







Fig. 8

Fig. 9






Fig. 10A




Fig. 10B




Fig. 11




Fig. 12

Fig. 13A




Fig. 13B




Fig. 14A




Fig. 14B

